Part I. General/Backgroundn n Chemoradiation: Biological Principles and Perspectivesn Hak Choy and Robert M. MacRaen n Fluoropyrimidines as Radiation Sensitizersn Muhammad Wasif Saif and Robert B. Diasion n Part II. Mechanisms of Interaction of Specific Chemotherapeutic Agents with Radiationn n The Role of Platinum Complexes in Combined Modality Therapyn Beverly A. Teichern n Taxanes in Combined Modality Therapyn Robert M. MacRae and Hak Choyn n Camptothecin Radiation Sensitizationn Tyvin A. Richn n The Role of Gemcitabine in Combined Modality Therapyn Jerome Landry, William Blackstock, Robert M. MacRae, Gary Yang, and Hak Choyn n Part III. Clinical Applicationsn n Chemoradiation Strategies for Patients with Malignant Gliomasn Heather A. Curry and Walter J. Curran, Jr.n n Combined Modality Strategies in the Treatment of Head and Neck Cancern Cathy Eng and Everett E. Vokesn n The Role of Combined Modality Therapy for Stage III Nonsmall-Cell Lung Cancern Roger W. Byhardtn n Combined Modality Treatment of Small-Cell Lung Cancern Julie R. Brahmer, Larry Kleinberg, and David S. Ettingern n The Role of Chemoradiation in the Management of Esophageal Cancern Arlene Forastiere and Bapsi Chakn n Combined Modality Therapy in Locally Advanced Breast Cancern Silvia C. Formenti and Matthew Volmn n Combined Modality Therapy for Gastric, Pancreatic, and Biliary Tract Carcinomasn Alexandria Phan and Jaffer A. Ajanin n Chemoradiation in Therapy for Colon and Rectum Carcinoman Jason H. Lee and Christopher G. Willettn n Chemoradiotherapy in Muscle-Invasive Bladder Cancern Bruce J. Rothn n The Role of Combined Chemotherapy and Radiation Therapy in the Treatment of Gynecologic Malignanciesn Patricia J. Eifeln n Part IV. Specific Molecular Targeted Agentsn n Overview of Specific Molecular Targeted Agents for Combined Modality Therapyn Scott Saxman and Janet Danceyn n Receptor Tyrosine Kinases as Therapeutic Targets in Solid Tumorsn Stacy L. Moulder and Carlos L. Arteagan n Adenoviral p53 Gene Therapy Strategies in Nonsmall-Cell Lung Cancern Stephen G. Swisher and Jack A. Rothn n Tumor Microvasculature as a Therapeutic Target During Radiotherapyn Dennis E. Hallahan and Don Stacyn n Cancer Drug Discovery and Development: Maximizing the Therapeutic Potential of Matrix Metalloproteinase Inhibitors for the Treatment of Cancern Jeffrey S. Humphrey, Karen Price, Elora Gupta, Andrew Baxter, John Bird, Daryl Sonnichsen, and Joseph Naglichn n The Role of Cyclooxygenase-2 Inhibitors in Combined Modality Therapyn Hong Pyo, Raymond N. DuBois, and Hak Choyn n Index
Internationally recognized experts in cancer biology and clinical research review the present status of the multimodality approach to the management of solid tumors and speculate on possible future strategies for chemoradiation therapy. The authors detail applications of combined modality therapy in lung, esophageal, breast, gastric, pancreatic, colon, and rectal cancers. They also show how radiation interacts with such chemotherapeutic agents as the platinum complexes, taxanes, and gemcitabine in the treatment of malignant gliomas, and head and neck cancer. A review of how to integrate new specific molecular targeted agents into multimodality therapy in the future.